Locations:
SearchAdvertisement
… are not a contraindication to COVID-19 therapies, liver enzymes should be carefully monitored in all hospitalized COVID-19 patients.In patients with severe COVID-19, liver injury appears to be common and is associated …
… the pandemic was ensuring that we continued to provide timely access to care,” he says. “Now that COVID-19 has been with us for a while, we are figuring out the best ways to manage …
… women and their babies.”The limited research that has been done on this population has indicated that COVID-19 may pose a significant risk. One early study from the CDC looked at 43 COVID-19 …
… burnout. That’s because neurologists report some of the highest rates of physician burnout and because the COVID-19 pandemic has tended to exacerbate burnout.So observes clinical health psychologist Amy Sullivan, PsyD, ABPP, Director …
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
As the virus (SARS-CoV-2) that causes COVID-19 continues to become better understood, several transmission routes and risk factors have been identified. These insights have been summarized by Ryan Miller, DO, and Kristin …
While reports abound about how the COVID-19 pandemic is fueling a surge in virtual outpatient visits, it’s likewise accelerating the adoption and evolution of telemedicine use in inpatient settings.“This public health crisis …
… based advice on how to build a highly functional endoscopic operations group within an institution.How did COVID-19 impact your presidency?Dr. Vargo: We had to cancel Digestive Disease Week, which has massive repercussions …
… Department of Quantitative Health Sciences.The investigation provides important perspective for clarifying the long-term effects of COVID-19. T2DM is already regarded as a risk factor for severe illness from COVID-19. More than …
… protocol treatment, the median time from diagnosis to surgery for patients treated with TNT in the COVID-19-era group also was significantly longer compared to patients treated with TNT in the pre-COVID-19 …
The monoclonal antibody canakinumab does not accelerate clinical improvement within two weeks of therapy among patients with COVID-19-associated myocardial injury and increased inflammation, finds a phase 2 study published online in the European …
Advertisement
Advertisement